The FDA has given priority review status to Boehringer Ingelheim’s new drug application re nintedanib for the treatment of people with idiopathic pulmonary fibrosis, a rare, progressive and fatal lung disease that affects as many as 132,000 Americans … more

The Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product from Eli LIlly and Boehringer Ingelheim, for the treatment of type 1 and type 2 diabetes. The product is the first biosimilar insulin recommended for approval in the European Union … more

The FDA has granted breakthrough therapy designation to Boehringer Ingelheim’s idarucizumab, an investigational fully humanized antibody fragment, or Fab, being studied as a specific antidote for Pradaxa (dabigatran etexilate mesylate) … more

German contractor Evotec has met another milestone in its arrangement with Boehringer Ingelheim by moving a respiratory compound into preclinical study … more